علاج الجدري المائي الشديد في المرضى المثبطين المناعة وغيرهم من الفئات عالية الخطورة

References

• Those with severe disease (e.g., haemorrhagic disease, confluent lesions, sepsis, encephalitis, or other conditions requiring hospitalisation).
• Those who are immunocompromised (e.g., acquired immune deficiency syndrome with CD4 count <200 cells/µL, leukaemia, lymphoma, generalised malignancy, solid organ transplantation, therapy with alkylating agents, antimetabolites, radiation, tumour necrosis factor inhibitors, high-dose corticosteroids, hematopoietic stem cell transplant recipient <24 months post-transplant or ≥24 months but with graft-versus-host disease or disease relapse, or having autoimmune disease with immunodeficiency as a clinical component).
• Paediatric populations, particularly patients younger than 8 years of age.
• Those with one or more complications (e.g., secondary bacterial skin infection; gastroenteritis with severe nausea/vomiting, diarrhoea, or dehydration; bronchopneumonia; concurrent disease or other comorbidities).

• 5 mg/kg body weight, intravenous.
• Induction treatment: Intravenous infusion at a constant rate over 1 hr administered once weekly for two consecutive weeks.
• Maintenance treatment: Beginning two weeks after the completion of induction treatment, intravenous infusion at a constant rate over 1 hour administered once every two weeks.
• Administration of Probenecid 2 g po 3 hours before Cidofovir, and 1 g 2–8 hours post Cidofovir is recommended for most indications to increase blood levels.